Cocrystal Pharma Inc.

Ticker

COCP

Website

Sector

Biotech

Tearsheet

Why Invest

Applying proprietary structure-based drug discovery platform and Nobel Prize-winning expertise to develop broad-spectrum direct acting antivirals with high barriers to resistance. Addresses large market opportunities for the treatment of acute and chronic viral diseases including COVID-19, influenza, hepatitis C and norovirus gastroenteritis. Initiated Phase 1 trial with potent, broad-spectrum treatment for seasonal and pandemic influenza A, with subject enrollment expected in 1Q22. Advancing 3 COVID-19 programs with goal of initiating two Phase 1 trials with compounds for intranasal/pulmonary and oral delivery in 2022. Cost-efficient business model with no debt and capital sufficient to fund planned operations with $61M in cash at 9?30/21.

  

  1. Focuses on developing novel antiviral therapeutics for hepatitis, influenza and noroviruses. Cost-efficient business model with no debt and capital